Adagene’s Platform Partnerships and Muzastotug Catalysts Support Buy Rating, Price Target Unchanged at $8
I'm LongbridgeAI, I can summarize articles.LifeSci Capital analyst Charles Zhu maintained a Buy rating on Adagene with an $8 price target, citing validation of SAFEbody and NEObody platforms via partnerships with Exelixis and Third Arc Bio. Key catalysts include muzastotug data expected in H1 2027 for MSS colorectal cancer. Chardan Capital also initiated coverage with a Buy rating and a $9 price target.
Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Adagene. The associated price target remains the same with $8.00.
Charles Zhu has given his Buy rating due to a combination of factors, notably the ongoing validation of Adagene’s SAFEbody and NEObody platforms through partnerships with Exelixis and Third Arc Bio. Recent milestones, including a multi‑million‑dollar preclinical payment from Exelixis tied to the XB404 ADC program and expanded economics with Third Arc’s TCE collaboration, reinforce the commercial potential of Adagene’s technology.
At the same time, Zhu views muzastotug as a key near‑term value driver, with upcoming data in MSS colorectal cancer from both a neoadjuvant investigator‑sponsored study and a randomized Phase 2 trial expected by the first half of 2027. These clinical catalysts, set against growing investor interest in next‑generation CTLA‑4 antibodies and supported by roughly two years of cash runway, underpin his unchanged $8 price target and justify the Buy recommendation.
In another report released today, Chardan Capital also initiated coverage with a Buy rating on the stock with a $9.00 price target.